Lung Cancer
Volume 45 , Pages S73-S76 , August 2004

Positron emission tomography in the diagnosis of mesothelioma

  • Uwe Haberkorn

      Affiliations

    • Corresponding Author InformationTel.: +49-6221-567-731; fax: +49-6221-565-473.

References 

  1. Ho L, Sugarbaker DJ, Skarin AT. Malignant pleural mesothelioma. Cancer Treat. Res. 2001;105:327–373
  2. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest. 1998;114:713–722
  3. Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, et al.  Over-expression of facilitative glucose transporter genes in human cancer. Biochem. Biophys. Res. Commun. 1990;170:223–230
  4. Haberkorn U, Ziegler SI, Oberdorfer F, Trojan H, Haag D, Peschke P, et al.  FDG uptake tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl. Med. Biol. 1994;21:827–834
  5. Carretta A, Landoni C, Melloni G, Ceresoli GL, Compierchio A, Fazio F, et al.  18-FDG positron emission tomography in the evaluation of malignant pleural diseases—a pilot study. Eur. J. Cardiothorac. Surg. 2000;17:377–383
  6. Buchmann I, Guhlmann CA, Elsner K, Gfrorer W, Schirrmeister H, Kotzerke J, et al.  F-18-FDG PET for primary diagnosis differential diagnosis of pleural processes. Nuklearmedizin. 1999;38:319–322
  7. Schneider DB, Clary-Macy C, Challa S, Sasse KC, Merrick SH, Hawkins R, et al.  Positron emission tomography with F-18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 2000;120:128–133
  8. Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al.  Dual time point -FDG PET imaging for differentiating malignant from inflammatory processes. J. Nucl. Med. 2001;42:1412–1417
  9. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J. Nucl. Med. 1999;40:1241–1245
  10. Haberkorn U, Strauss LG, Dimitrakopoulou A, Seiffert E, Oberdorfer F, Ziegler S, et al.  Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J. Nucl. Med. 1993;34:12–17
  11. Haberkorn U, Strauss LG, Dimitrakopoulou A, Engenhart R, Oberdorfer F, Ostertag H, et al.  PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J. Nucl. Med. 1991;32:1485–1490
  12. Haberkorn U, Bellemann ME, Gerlach L, Morr I, Trojan H, Brix G, et al.  Uncoupling of 2-fluoro-2-deoxyglucose transport and phosphorylation in rat hepatoma during gene therapy with HSV thymidine kinase. Gene Ther. 1998;5:880–887
  13. Marom EM, Erasmus JJ, Pass HI, Patz EF. The role of imaging in malignant pleural mesothelioma. Semin. Oncol. 2002;29:26–35

PII: S0169-5002(04)00176-X

doi: 10.1016/j.lungcan.2004.04.016

Lung Cancer
Volume 45 , Pages S73-S76 , August 2004

Article Tools